Dublin, Aug. 30, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Ophthalmology Drugs Market to 2022 - Angiogenesis Modulators and Gene Therapies to Boost Overall Revenue within the Forecast Period" report to their offering. The ophthalmological disorders market, which is set to almost double from $13.7 billion in 2015 to $26 billion by 2022 at a compound annual growth rate (CAGR) of 9.48%, will see the entry of a range of new companies over the forecast period as the treatment space is transformed by patent expiries and new product entrants, according to the publisher. This report states that the ophthalmology landscape, which covers glaucoma, age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and dry eye syndrome, will see top companies lose a degree of dominance as smaller, specialized companies gain ground. One of our analysts explains: Four new companies - Ophthotech, Spark Therapeutics, Aerie Pharmaceuticals, and Eleven Biotherapies - will enter the market during the forecast period, and some of them are anticipated to become key players within this timeframe. The current major players in the market, including Bayer and Novartis, are expected to maintain their strong positions. However, the new entrant Ophthotech is forecast to overtake Roche in terms of total revenue created within ophthalmology by 2022. It is anticipated that Ophthotech's Fovista will be approved during the forecast period, and reach blockbuster status within three years of being on the market, generating overall revenue of approximately $2.3 billion. Its approval in 2017 is forecast to generate revenue of $120 million, increasing at an extremely rapid CAGR of 52.44% between 2017 and 2022. Ophthotech secured the drug through a licensing agreement with Novartis, and Fovista is expected to have a greater effect on the market than older drugs such as Santen's Cosopt/Trusopt, which has lower revenue due to generic competition. Scope
- Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?
- The ophthalmology pipeline is large and diverse, and contains 734 products. How does the composition of the pipeline compare with that of the existing market?
- What mechanisms of action and molecule types are most commonly being trialed in pipeline products in the various key indications?
- Which products will contribute to market growth most significantly, and which will achieve blockbuster status?
- Will the current market leaders retain their dominance over the forecast period, and how is their revenue share of the dermatology market set to change?
Key Topics Covered: 1 Tables & Figures
2 Introduction 2.1 Therapy Area Introduction 2.2 Symptoms 2.3 Etiology and Pathophysiology 2.4 Co-morbidities and Complications 2.5 Epidemiology Patterns; Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates 2.6 Treatment
3 Key Marketed Products 3.1 Overview 3.2 Lucentis (ranibizumab) 3.3 Eylea (aflibercept) 3.4 Avastin (bevacizumab) 3.5 Restasis (cyclosporine) 3.6 Alphagan (brimonidine tartrate) 3.7 Lumigan (bimatoprost) 3.8 Xalatan (latanoprost)
4 Pipeline Landscape Assessment 4.1 Overview 4.2 Pipeline Development Landscape 4.3 Mechanisms of Action in the Pipeline 4.4 Clinical Trials 5 Multi-Scenario Market Forecast to 2022 5.1 Overall Market Size 5.2 Generic Penetration 5.3 Revenue Forecast by Molecular Target 6 Company Analysis and Positioning 6.1 Revenue and Market Share Analysis by Company 6.2 Company Landscape 6.3 Marketed and Pipeline Portfolio Analysis
7 Strategic Consolidations 7.1 Licensing Deals 7.2 Co-development Deals 8 Appendix For more information about this report visit http://www.researchandmarkets.com/research/lts4lg/global Related Topics: Genomics
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716
